Negative drug results cost AbbVie billions of dollars in market value and convinced analysts that Bristol Myers had placed a ...

Shares in AbbVie slumped Monday after the company disclosed its psychiatric medicine emraclidine didn’t best placebo in two ...

Developer Autolus set a list price of $525,000 for its new cell therapy, which it will sell for a type of leukemia under the ...

The Food and Drug Administration has cleared Novavax to move forward with testing of a combination vaccine for COVID-19 and ...

“As the industry transitions from traditional drug discovery and life sciences R&D to faster-paced, complex modalities, ...

The president-elect has said he’ll let Robert F. Kennedy Jr. “go wild” on healthcare, while many expect a leadership change ...

Past comments by Robert F. Kennedy Jr. hint at the ideas he might advocate for if given a role in the incoming Trump ...

Patient advocates are hoping for change under new director Michelle Tarver, while industry groups hope she will build on ...

Quantiphi Global Head of Healthcare and Life Sciences Barinder Marhok said the partnership marries DDReg’s expertise in ...

Elevidys sales have increased since the FDA made a controversial choice to expand the therapy's use. Meanwhile, Sarepta is ...

Pioneers like Alnylam Pharmaceuticals have led the RNA interference field for years. Now, a crop of young biotechs is ...

After Kalaris and AlloVir combine, the new company will have about $100 million to advance a treatment for age-related ...